Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking for Compassionate Treatment in Pediatric Patients With Progressive Keratoconus

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00925327

Acronym

CXL

Enrollment

Registered

2009-06-22

Start date

Unknown

Completion date

Unknown

Last updated

2009-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Progressive Keratoconus

Brief summary

This is a compassionate treatment protocol for the use of the UV-X system for corneal collagen cross-linking (CXL) in eyes with progressive keratoconus in patients who have conditions that limit their capacity to comply with the cross-linking treatment procedures required by ongoing clinical trials.

Detailed description

This is a non-randomized study. All eyes that qualify for the study will receive the cross-linking (CXL) procedure. Corneal collagen cross-linking is performed as a single treatment. Depending on the patient's condition, the CXL procedure may be performed under sedation or anesthesia. Subjects are followed for 12 months after the procedure to evaluate the long term effects of corneal collagen cross-linking.

Interventions

OTHERCorneal collagen cross-linking with riboflavin/UVA light

Corneal collagen cross-linking with riboflavin/UVA light

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

6 Years to 18 Years

Healthy volunteers

Inclusion criteria

* Age 6 to 18 years * Having a diagnosis of progressive keratoconus * Signed written informed consent * Having a condition that limits the patient's capacity to comply with the cross-linking treatment procedures and/or the diagnostic tests and measurements required by the ongoing clinical studies * Willingness and ability to comply with schedule for follow-up visits

Exclusion criteria

* Corneal pachymetry at the screening exam that is \<400 microns at the thinnest point * Previous ocular condition in the eye(s) to be treated that may predispose the eye for future complications, for example (herpes simplex, herpes zoster keratitis, recurrent erosion syndrome, corneal melt, or corneal dystrophy, etc.) * A history of delayed epithelial healing in the eye(s) to be treated * Pregnancy or lactation during the course of the study * A known sensitivity to study medications

Design outcomes

Primary

Measure	Time frame
Change in keratometry	3 Months

Secondary

Measure	Time frame
Change in manifest refraction spherical equivalent	3 Month

Countries

United States

Contacts

Primary ContactErin D. Stahl, MD

816-234-3046

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026